Initially was concerned about the cash balance and the threat of...

Initially was concerned about the cash balance and the threat of a CR. But the detail on page 4 of today's announcement regarding a corporate advisory mandate provides the company with capital and SP appreciation.

35,000,000 x 0.065 = + $2.275m

Couple this with the fact the organisation has stated it will seek to accelerate commercial negotiations with potential strategic partners & impending final results of Phase I/II ASD clinical trial in June 2022. Oh and don't forget that parents lobbied the ethics committee at the hospital for their children to stay on Neurotech's drug. I look forward to the efficacy results.

Exciting times ahead. Unfortunately, I do not hold as much as I once did but I am very contempt with my holding here.